Value20202021202220232024TTMSelling/general/admin expenses18.37 M13.9 M10.21 M9.89 M9.47 M11.57 MResearch & development0—————Operating income70.21 M80.75 M10.26 M-25.44 M-20.54 M-30.79 MNon-Operating Income, Total————11.41 M—Interest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses————2.92 M—Unusual income/expense————8.5 M—Pretax income103.86 M96.92 M79.97 M96.36 M128.03 M2.36 MEquity in earnings1.18 M3 000862 K00—Taxes82 K160 K189 K458 K1.79 M66 KNon-controlling/minority interest00————After tax other income/expense226 K24 K106 K2 0000—Net income before discontinued operations103.77 M87.57 M-79.78 M95.9 M126.23 M246.87 MDiscontinued operations66.75 M4.6 M108.09 M00—Net income170.52 M92.17 M28.32 M95.9 M126.23 M246.87 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders170.52 M92.17 M28.32 M95.9 M126.23 M425.87 MBasic earnings per share (Basic EPS)—-0.470.14-0.39-0.47-1.38Diluted earnings per share (Diluted EPS)—-0.470.14-0.39-0.47-1.38Average basic shares outstanding—197.76 M200.36 M244.54 M267.73 M1.17 BDiluted shares outstanding—197.76 M200.36 M244.54 M267.73 M1.17 BEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)17.52 M13.76 M10.77 M6.67 M4.53 M2.72 M
Precigen Inc
Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari.
Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.